Dashboard
Manage Tickers

BTAI BioXcel Therapeutics, Inc.

Nasdaq bioxceltherapeutics.com


$ 1.91 $ -0.15 (-7.32 %)    

Monday, 03-Nov-2025 18:19:31 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 631.18 $ 3.01 (0.48 %)
DIA $ 472.86 $ -2.20 (-0.46 %)
SPY $ 682.58 $ 1.28 (0.19 %)
TLT $ 89.66 $ -0.55 (-0.61 %)
GLD $ 367.55 $ 0.66 (0.18 %)
$ 1.9
$ 1.99
$ 1.89 x 183
$ 1.91 x 10
$ 1.90 - $ 2.00
$ 1.17 - $ 12.16
576,883
na
29.84M
$ 1.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bioxcel-therapeutics-announced-results-from-the-correlation-study-related-to-exploratory-efficacy-outcomes-from-serenity-at-home-trial-the-results-along-with-the-data-from-the-serenity-at-home-trial-will-be-included-in-the-supplemental-new-drug-application-submission-planned-for-1q26
Bioxcel Therapeutics Announced Results Fro...
10/14/2025 11:07:30

The standard method for measuring acute agitation associated with schizophrenia and bipolar disorder is the Positive and Negati...

bioxcel-therapeutics-announces-compliance-with-nasdaq-mvls-rule-following-september-17-notice-from-listing-qualifications-department
BioXcel Therapeutics Announces Compliance ...
09/18/2025 11:02:54

hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on BioX...
09/15/2025 12:03:35

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

mizuho-maintains-neutral-on-bioxcel-therapeutics-raises-price-target-to-4
Mizuho Maintains Neutral on BioXcel Therap...
09/12/2025 11:57:55

Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target fro...

bioxcel-drug-calms-agitation-at-home-for-schizophrenia-bipolar-patients
BioXcel Drug Calms Agitation At Home For S...
09/10/2025 19:08:13

BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its a...

bioxcel-therapeutics-announced-topline-exploratory-efficacy-data-from-serenity-at-home-pivotal-phase-3-safety-trial-which-demonstrated-bxcl501-had-continued-effects-and-consistent-benefit-with-repeat-dosing-for-agitation-associated-with-bipolar-disorders-or-schizophrenia
Bioxcel Therapeutics Announced Topline Exp...
09/10/2025 10:31:58

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 tre...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on BioX...
08/28/2025 11:11:29

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/27/2025 17:06:12

bioxcel-seeks-fda-label-expansion-for-schizophrenia-treatment
BioXcel Seeks FDA Label Expansion For Schi...
08/27/2025 16:01:18

BioXcel's Phase 3 trial shows BXCL501 safely reduces agitation in schizophrenia patients, supporting plans for an FDA label...

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
08/27/2025 11:25:11

bioxcel-therapeutics-shares-to-resume-trading-at-730am-et
BioXcel Therapeutics Shares To Resume Trad...
08/27/2025 11:22:29

bioxcel-eyes-q1-2026-snda-for-igalmi-at-home-use-following-bxcl501-phase-3-trial-results
BioXcel Eyes Q1 2026 sNDA For IGALMI At-Ho...
08/27/2025 11:10:07

Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 i...

bioxcel-therapeutics-says-bxcl501-meets-primary-endpoint-in-serenity-at-home-trial-for-bipolar-and-schizophrenia-agitation
BioXcel Therapeutics Says BXCL501 Meets Pr...
08/27/2025 11:06:30

BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes...

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
08/27/2025 10:55:04

why-mongodb-shares-are-trading-higher-by-31-here-are-20-stocks-moving-premarket
Why MongoDB Shares Are Trading Higher By 3...
08/27/2025 10:05:03

bioxcel-stock-surges-19-in-after-hours-trading-what-you-need-to-know
BioXcel Stock Surges 19% In After-Hours Tr...
08/27/2025 06:55:17

BioXcel Therapeutics shares surged over 19% after hours ahead of key Phase 3 trial results for its at-home agitation treatment,...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/26/2025 21:08:52

bioxcel-to-reveal-phase-3-data-for-at-home-agitation-treatment-bxcl501-in-investor-call-on-august-27
BioXcel To Reveal Phase 3 Data For At-Home...
08/26/2025 20:08:59

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformati...

bioxcel-reaches-key-milestone-in-phase-3-trial-for-at-home-agitation-treatment-results-coming-in-august
BioXcel Reaches Key Milestone in Phase 3 T...
08/19/2025 11:06:44

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformati...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION